BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
|Articles|November 2, 2001
- Pharmaceutical Technology-11-02-2001
- Volume 25
- Issue 11
Truth in Outsourcing
Author(s)William B. Bierce
Contract service providers and clients alike must be realistic and forthcoming about their expectations to accomplish a truthful outsourcing partnership.
Advertisement
Articles in this issue
about 25 years ago
blankabout 25 years ago
Manufacturers Face Challenges and Regulatory Changesabout 25 years ago
One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluationabout 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited Part IIabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
1074 Revision Needs Formulator Feedback: AAPS PharmSci 360 2026
5